AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
Executive Summary
AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab